exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089054 RNA Name: hsa-miR-545-3p RNA Type: miRNA Chromosome: chrX Starnd: - Coordinate: Start Site(bp): 74287126 End Site(bp): 74287147 External Links: hsa-miR-545-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ANKRD50 chr4 124664048 124712732 - ARRB2 chr17 4710596 4721499 + BVES chr6 105096822 105137157 - CREBRF chr5 173056352 173139284 + FAM89A chr1 231018958 231040254 - NAV1 chr1 201622885 201826969 + SPECC1 chr17 20009344 20319026 + TOB2 chr22 41433494 41446801 - TRIM33 chr1 114392790 114511203 - UTRN chr6 144285701 144853034 + WDR4 chr21 42843094 42879568 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001409 chr4 48835417 48859382 + hsa_circ_0000458 chr12 124071293 124074996 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0001452 chr4 153562079 153574079 - hsa_circ_0001263 chr3 5215701 5216099 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC114980.1 chr5 93860669 93863825 - AC125257.1 chr17 41848518 41851447 - AC245033.4 chr15 82533175 82540008 - GAS5 chr1 173858559 173868882 - LINC00476 chr9 95759231 95876049 - MALAT1 chr11 65497688 65506516 + MCM3AP-AS1 chr21 46229196 46259390 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + RRN3P2 chr16 29074976 29116718 + SNHG1 chr11 62851984 62855953 - TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.